More than 16% of eligible individuals get screened for lung cancer in Massachusetts. Only 1% do so in California. The national average is unfortunately closer to the latter extreme, at 5.8%.

An established radiopharmaceutical can now be applied with the FDA’s blessing when symptoms of cognitive decline point to the second most common form of degenerative dementia (after only Alzheimer’s disease).  

RapidAI has been cleared for U.S. marketing of updated AI-outfitted software that quickly detects or rules out acute brain hemorrhage on unenhanced CT.

Lyme disease patients treated for “brain fog” may develop compensatory alterations in white matter that show up on MRI and correspond—unexpectedly—with slow but sound cognitive performance.

James Udelson, MD, an investigator involved with the PRECISE trial, explained how patient outcomes were improved by 70% from the current standard of care.

Contrary to older research that showed neuroimaging emerging as the single most dominating cost contributor in ischemic stroke care for older Americans, a new study shows treatment and other line items account for bigger slices of the bill.

Pregnant women who felt stressed by healthcare disruptions caused by the COVID-19 pandemic radiated the unease to their developing offspring. The effects were observable on fetal MRI of both brainstem structure and functional activity.

Bhvita Jani, research manager, Signify Research, explains some key trends and technology advances in the magnetic resonance imaging (MRI) market leading into the Radiological Society of North America (RSNA) 2022 meeting.